Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 22
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Difficulties during delivery, brain ventricle enlargement and cognitive impairment in first episode psychosis

  • Verdolini, Norma|||0000-0001-9488-2881
  • Garcia Rizo, Clemente|||0000-0002-4855-1608
  • Mezquida, Gisela|||0000-0002-6080-2203
  • Janssen, Joost|||0000-0001-7613-2067
  • Corripio, Iluminada|||0000-0003-2562-711X
  • Bioque, Miquel|||0000-0001-6887-7149
  • Lobo, Antonio|||0000-0002-9098-655X
  • Vieta, Eduard|||0000-0002-0548-0053
  • Mané, Anna|||0000-0003-2127-349X
  • Roldan-Bejarano, Alexandra|||0000-0001-9905-3943
  • Cuesta, M.J.
  • Parellada, Mara|||0000-0001-7977-3601
  • Bernardo, Miquel|||0000-0001-8748-6717
  • Costas-Carrera, A.
  • Valli, Isabel|||0000-0003-3052-7383
  • Sánchez Torres, Ana Maria|||0000-0002-9505-2406
  • González-Pinto, Ana|||0000-0002-2568-5179
  • Rapado-Castro, M.
  • de la Serna, Elena|||0000-0002-7869-9881
  • Crossley, N.
  • Penadés, R.
Background Patients with a first episode of psychosis (FEP) display clinical, cognitive, and structural brain abnormalities at illness onset. Ventricular enlargement has been identified in schizophrenia since the initial development of neuroimaging techniques. Obstetric abnormalities have been associated with an increased risk of developing psychosis but also with cognitive impairment and brain structure abnormalities. Difficulties during delivery are associated with a higher risk of birth asphyxia leading to brain structural abnormalities, such as ventriculomegaly, which has been related to cognitive disturbances. Methods We examined differences in ventricular size between 142 FEP patients and 123 healthy control participants using magnetic resonance imaging. Obstetric complications were evaluated using the Lewis-Murray scale. We examined the impact of obstetric difficulties during delivery on ventricle size as well as the possible relationship between ventricle size and cognitive impairment in both groups. Results FEP patients displayed significantly larger third ventricle size compared with healthy controls. Third ventricle enlargement was associated with diagnosis (higher volume in patients), with difficulties during delivery (higher volume in subjects with difficulties), and was highest in patients with difficulties during delivery. Verbal memory was significantly associated with third ventricle to brain ratio. Conclusions Our results suggest that difficulties during delivery might be significant contributors to the ventricular enlargement historically described in schizophrenia. Thus, obstetric complications may contribute to the development of psychosis through changes in brain architecture.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Risk scores predicting disease progression in early-stage chronic lymphocytic leukemia, Comparative analysis and usefulness of IGHV subset #2 to improve their accuracy

  • Arguello-Tomas, Miguel|||0000-0002-3329-4151
  • Mozas, Pablo|||0000-0001-9528-4971
  • Albiol, Nil|||0000-0003-2942-1362
  • López-Esteban, Miguel
  • Sierra, Jorge|||0000-0002-7966-0356
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Martínez-Laperche, Carolina
  • Moga, Esther|||0000-0003-4264-6910
  • Piñeyroa, Juan A.
  • Delgado, Julio|||0000-0002-5157-4376
  • Osorio, Santiago
  • Moreno, Carol|||0000-0003-3275-0271
Background: Overall, the prognosis of patients with chronic lymphocytic leukemia (CLL) in the early phase of the disease (Rai 0, Binet A) is favorable; some patients never require therapy. However, some patients require intervention shortly after diagnosis. In the past decade, several risk scores (RS) have been developed to predict disease progression, yet some patients are misclassified. On the other hand, IGHV subset 2 (IGHV2) predicts poor outcomes. Methods: A retrospective and multicentric study was conducted to compare the accuracy of five different RS (IPS-E, CR0, AIPS-E, CLL-IPI, and Barcelona-Brno) to predict disease progression in 781 stage A previously untreated patients with CLL. As an exploratory analysis, it was further investigated whether the inclusion of the IGHV2 as a poor prognostic parameter improved the accuracy of RS. Results: All the scores identified a similar group of patients with CLL in early stage with low-, intermediate-, and high-risk progression. Discrimination was high and similar in all RS (c-index = 0.74-0.79, area under the curve = 0.7-0.75), as well as calibration (p =.98) and parsimony, although CLL-IPI showed the best results (Akaike information criterion = 441). A total of 34.4% of patients were categorized within the same RS and concordance was at least moderate between RS. Conclusion: Moreover, the results suggest that IGHV2 may improve the accuracy of RS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical and immunologic characteristics of nonhematologic autoimmune disorders in chronic lymphocytic leukemia

  • Arguello-Tomas, Miguel|||0000-0002-3329-4151
  • Lynton-Pons, Elionor|||0000-0001-5375-7195
  • Albiol, Nil|||0000-0003-2942-1362
  • López Ferrer, Anna|||0000-0002-2121-963X
  • Sierra, Jorge|||0000-0002-7966-0356
  • Moga, Esther|||0000-0003-4264-6910
  • Moreno, Carol|||0000-0003-3275-0271
Background: Autoimmune disorders (AIDs) are frequent in patients with chronic lymphocytic leukemia (CLL). There is little information on the clinical characteristics and pathogenesis of nonhematologic AIDs in patients with CLL, although both entities present immunologic alterations in their clinical onset. Methods: This single-center series included 907 patients with CLL who had a median follow-up of 6.6 years (range, 0.1-36.4 years). Results: In total, 156 patients developed an AID, including 99 patients (10.9%) with nonhematologic AIDs, 46 (5.1%) with autoimmune cytopenia (AIC), and 11 (1.2%) with both; autoimmune hypothyroidism and psoriasis were the most frequent AIDs. Patients with nonhematologic AIDs had low-risk genetic features and were related to a better time to first treatment than patients with AIC (13.8 vs. 5.5 years; p <.001). Patients with both CLL and psoriasis had the lowest risk of progression. The authors performed a T-cell/natural killer-cell and cytokine assessment among patients who had CLL with and without psoriasis. An unsupervised hierarchical clustering revealed a distinct cluster characterized by an expansion of T-helper 17 cells, T-regulatory cells, interleukin-17F, and interleukin-23. Conclusions: The current findings suggest that nonhematologic AIDs are prevalent in patients with CLL, and these patients have a better prognosis than patients who have AIC. The expansion of interleukin-17F-producing cells in patients with psoriasis may explain their good prognosis.
Repisalud
Publication Artículo científico (JournalArticle)

Transferable AmpCs in Klebsiella pneumoniae: interplay with peptidoglycan recycling, mechanisms of hyperproduction, and virulence implications

  • Barceló, Isabel M
  • Escobar-Salom, Maria
  • Cabot, Gabriel
  • Perelló-Bauzà, Pau
  • Jordana-Lluch, Elena
  • Taltavull, Biel
  • Torrens, Gabriel
  • Rojo-Molinero, Estrella
  • Zamorano, Laura
  • Perez Gomez, Astrid
  • Oliver, Antonio
  • Juan, Carlos
Chromosomal and transferable AmpC β-lactamases represent top resistance mechanisms in different gram-negatives, but knowledge regarding the latter, mostly concerning regulation and virulence-related implications, is far from being complete. To fill this gap, we used Klebsiella pneumoniae (KP) and two different plasmid-encoded AmpCs [DHA-1 (AmpR regulator linked, inducible) and CMY-2 (constitutive)] as models to perform a study in which we show that blockade of peptidoglycan recycling through AmpG permease inactivation abolished DHA-1 inducibility but did not affect CMY-2 production and neither did it alter KP pathogenic behavior. Moreover, whereas regular production of both AmpC-type enzymes did not attenuate KP virulence, when blaDHA-1 was expressed in an ampG-defective mutant, Galleria mellonella killing was significantly (but not drastically) attenuated. Spontaneous DHA-1 hyperproducer mutants were readily obtained in vitro, showing slight or insignificant virulence attenuations together with high-level resistance to β-lactams only mildly affected by basal production (e.g., ceftazidime, ceftolozane/tazobactam). By analyzing diverse DHA-1-harboring clinical KP strains, we demonstrate that the natural selection of these hyperproducers is not exceptional (>10% of the collection), whereas mutational inactivation of the typical AmpC hyperproduction-related gene mpl was the most frequent underlying mechanism. The potential silent dissemination of this kind of strains, for which an important fitness cost-related contention barrier does not seem to exist, is envisaged as a neglected threat for most β-lactams effectiveness, including recently introduced combinations. Analyzing whether this phenomenon is applicable to other transferable β-lactamases and species as well as determining the levels of conferred resistance poses an essential topic to be addressed. IMPORTANCE: Although there is solid knowledge about the regulation of transferable and especially chromosomal AmpC β-lactamases in Enterobacterales, there are still gaps to fill, mainly related to regulatory mechanisms and virulence interplays of the former. This work addresses them using Klebsiella pneumoniae as model, delving into a barely explored conception: the acquisition of a plasmid-encoded inducible AmpC-type enzyme whose production can be increased through selection of chromosomal mutations, entailing dramatically increased resistance compared to basal expression but minor associated virulence costs. Accordingly, we demonstrate that clinical K. pneumoniae DHA-1 hyperproducer strains are not exceptional. Through this study, we warn for the first time that this phenomenon may be a neglected new threat for β-lactams effectiveness (including some recently introduced ones) silently spreading in the clinical context, not only in K. pneumoniae but potentially also in other pathogens. These facts must be carefully considered in order to design future resistance-preventive strategies.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Tesis doctoral (DoctoralThesis)

Characterization of Tumor Cells and Immune Microenvironment Interactions in Non Small Cell Lung Cancer. Translational implications

  • Torres Martínez, Susana
[ES] En esta tesis, buscamos profundizar en el estudio del microambiente inmunitario del tumor (TME), lo que resultaría en una mejor caracterización del contexto inmunológico de los pacientes y la búsqueda de nuevos biomarcadores en el cáncer de pulmón. Se emplearon cultivos derivados de pacientes con cáncer de pulmón, y líneas celulares comerciales para ensayos de formación de tumoresferas y condiciones adherentes como control. Se analizó la expresión génica de diversos factores inmunorreguladores, observándose una mayor expresión de la mayoría de ellos en las tumoresferas en comparación con las células adherentes. Junto con la secreción, la Galectina-3 (GAL3 o LGALS3 cuando se referencian la proteína o el gen, respectivamente) se seleccionó como la molécula que podría tener una fuerte implicación en la modulación del TME. Los análisis proteicos confirmaron que la GAL3 aumentaba en las tumoresferas de cultivos de adenocarcinoma (ADC) y mostraba patrones de localización y expresión diferencial. Las vesículas extracelulares procedentes de tumoresferas exhibieron niveles altos de LGALS3. Además, revelamos que la GAL3 podría desempeñar un papel crucial como molécula inmunomoduladora en el TME, modulando la inmunosupresión a través de las células T reguladoras (TREGS). Esto se confirmó en muestras tumorales de pacientes, dónde los niveles de expresión altos de LGALS3, se correlacionaron con mayores niveles de TREGS, sugiriendo que los tumores pueden reclutar esta población a través de la GAL3. Posteriormente, se evaluaron los roles pronósticos y diagnósticos de la GAL3 soluble (sGAL3) y otros factores inmunorreguladores (sICOSL, sFGL1, sGAL1, sMICA, sMICB, sCD276) en una cohorte de 94 pacientes con cáncer de pulmón en estadios tempranos resecables (cohorte test). sFGL1, sGAL3 y su combinación mostraron una eficacia diagnóstica óptima para nuestros pacientes. El análisis de supervivencia demostró que, en la sub-cohorte de ADC, los pacientes con niveles altos de sGAL3 experimentaron una supervivencia libre de recaída (SLR) (p=0,048) y una supervivencia global (SG) más corta (p=0,021), mientras que no se observó ninguna asociación en la sub-cohorte de pacientes con carcinoma de células escamosas. El análisis multivariante indicó que sGAL3 podría ser un biomarcador pronóstico independiente para SLR y SG. La expresión génica de nuestro panel de factores inmunoreguladores también se analizó en un grupo independiente de 661 pacientes de TCGA (cohorte de validación), confirmando el valor pronóstico independiente de LGALS3 en la sub-cohorte de ADC para SLR (p=0,021) y SG (p=0,004). El papel diagnóstico, predictivo y pronóstico de estos factores se evaluó en muestras de plasma en el momento basal (PRE) y en la evaluación de la primera respuesta (FR) en una cohorte de 52 pacientes con cáncer de pulmón en estadio avanzado tratados en primera línea con pembrolizumab. sFGL1, sGAL3 y su combinación de nuevo ofrecieron una eficacia diagnóstica óptima para esta cohorte de pacientes. Los niveles de sGAL3 en FR y sMICB en PRE y FR se asociaron con un beneficio clínico en toda la cohorte y en la subcohorte de ADC. sCD276 también se asoció con la respuesta global en toda la cohorte y en la sub-cohorte de ADC. sMICB en FR se identificó como un biomarcador independiente para la supervivencia libre de progresión (SLP) en toda la cohorte y para SLP y SG en la sub-cohorte de ADC. Además, sGAL3 en PRE se encontró como un biomarcador independiente para SLP y SG en toda la cohorte y en FR se identificó como biomarcador independiente para SG en la sub-cohorte ADC. Una disminución en los niveles de sGAL3 en los pacientes en tratamiento se asoció con una reducción en la SG en toda la cohorte. En conclusión, nuestros hallazgos proporcionan información diagnóstica, pronóstica y predictiva relevante del rol de la GAL3 y otros factores inmunoreguladores para los pacientes con cáncer de pulmón y sirven como base para el desarrollo de nuevos biomarcadores y terapias., [CA] En aquest estudi, busquem profunditzar en l'estudi del microambient immunològic del tumor (TME), el que resultaria en una millor caracterització del context immunològic dels pacients i la recerca de nous biomarcadors en el càncer de pulmó. S'utilitzaren cultius de llarg termini establits a partir de pacients amb càncer de pulmó en etapa primerenca, i línies cel·lulars comercials per a assajos de formació de tumorsferes per a l'enriquiment de cèl·lules mares canceroses i condicions adherents com a control. S'analitzà l'expressió gènica de diversos factors immunoreguladors, i es va observar una major expressió de la majoria d'ells en les tumorsferes en comparació amb les cèl·lules adherents. Juntament la secreció, la Galectina-3 (GAL3 o LGALS3 quan es fa referència a la proteïna o al gen, respectivament) es va seleccionar com la molècula que podria tindre una forta implicació en la modulación del TME. Els anàlisis proteics van confirmar que la GAL3 augmentava consistentment en les tumorsferes de cultius d'adenocarcinoma de pulmó (ADC) i mostrava patrons de localització i expressió diferencial. Les vesícules extracel·lulars precedents de les tumorspheres també van exhibir nivells alts de LGALS3. Vam revelar que la GAL3 podria jugar un paper crucial com a molècula immunomoduladora expressada i secreta en el TME, modulant la immunosupressió a través de les cèl·lules T reguladores (TREGS). Això es va confirmar en mostres tumorals de pacients amb nivells d'expressió elevats de GAL3, que a més tenien majors nivells de TREGS. Posteriorment, es van avaluar els rols pronòstics i diagnòstics de la GAL3 soluble (sGAL3) i altres factors immunoreguladors (sICOSL, sFGL1, sGAL1, sMICA, sMICB, sCD276) en una cohort de 94 pacients amb càncer de pulmó en estadi primerenc (cohort de test). sFGL1, sGAL3 i la seua combinació van mostrar una eficàcia diagnòstica òptima en la nostra cohort. A més, l'anàlisi de supervivència de Kaplan-Meier va demostrar en la subcohort de ADC en estadi primerenc, que els pacients amb nivells alts de sGAL3 van experimentar una supervivència lliure de recaiguda (SLR) (p=0,048) i una supervivència global (SG) més curta (p=0,021), però no en la de carcinoma de cèl·lules escamoses. L'anàlisi multivariant va indicar que sGAL3 podria ser un biomarcador independent del pronòstic per a SG i SLR. L'expressió gènica de tots aquests factors immunoreguladors també es va analitzar en un grup independent de 661 pacients de TCGA (cohort de validació), confirmant el valor pronòstic independent de LGALS3 en la subcohort de ADC per a SLR (p=0,021) i SG (p=0,004). El paper diagnòstic, predictiu i pronòstic d'aquests factors immunoreguladors també es va avaluar en el moment basal (PRE) i en l'avaluació de la primera resposta (FR) en una cohort de 52 pacients amb cáncer de pulmó en estadi avançat tractats en primera línia amb pembrolizumab. sFGL1, sGAL3 i la seua combinació de nou van oferir una eficàcia diagnòstica òptima per als pacients d'aquesta cohort. Els nivells de sGAL3 en FR i sMICB en PRE i FR estaven associats amb un benefici clínic durador en tota la cohort i en la subcohort de LUAD. sCD276 també es va associar amb la resposta global en tota la cohort i en la subcohort de ADC. Un anàlisi de regressió de Cox va identificar sMICB en FR com a biomarcador independent per a la supervivència lliure de progressió (SLP) en tota la cohort i per a SLP i SG en la subcohort de ADC. sGAL3 en PRE es va trobar com a biomarcador independent per a SLP i SG en tota la cohort, i sGAL3 en FR es va identificar com a biomarcador independent per a SG en la subcohort de ADC. Una disminució en FR dels nivells de sGAL3 es va associar amb una reducció en la SG en tota la cohort. En conclusió, els nostres descobriments proporcionen informació rellevant sobre el rol diagnòstic y el pronòstic de la GAL3 y altres factor inmunoreguladors per als pacients amb càncer de pulmó i serveixen com a base per al desenvolupament de nous biomarcadors i teràpies., [EN] The complex field of immuno-oncology is constantly evolving, driven by cancer heterogeneity and the plasticity of the immune cells participating in this process. In this study we aim to delve deeper into the study of immune tumor microenvironment (TME), which will result in an improved characterization of patient`s immune contexture and the search for new biomarkers in lung cancer. In this thesis, long term patient derived lung cancer cell (PDLCC) and commercial cell lines cultures were employed for sphere-forming assays for cancer stem cells enrichment and adherent conditions for the control counterparts. Gene expression of immune-mediators was analyzed showing that expression levels of most selected genes were higher in tumorspheres compared with the adherent cells counterparts. Together with secretion, Galectin-3 (GAL3 or LGALS3 when protein or gene are referenced, respectively) was selected as the molecule that could have a strong implication in the modulation of TME. Immunoblot, flow cytometry and immunofluorescence analyses confirmed that GAL3 was consistently increased in tumorspheres from lung adenocarcinoma (LUAD) and showed differential localization and expression patterns. Extracelullar vesicles from tumorspheres also exhibited high levels of LGALS3. Next, we revealed that GAL3 could play a crucial role as an immunomodulatory molecule expressed and secreted in the TME, modulating immunosuppression through regulatory T cells (TREGS). This was confirmed in patient's tumor samples, where higher levels of LGALS3 correlated with increased TREGS, suggesting that tumors may be recruiting this population through GAL3. The prognostic and diagnostic roles of soluble GAL3 (sGAL3) and other immune-mediators (sICOSL, sFGL1, sGAL1, sMICA, sMICB, sCD276) were evaluated in a cohort of 94 early-stage lung cancer (test cohort). sFGL1, sGAL3 and its combination yielded optimal diagnostic efficacy in our patient's cohort. A Cox regression analysis revealed an association between sGAL3 and prognosis. Kaplan-Meier plots show that, in the early-stage LUAD subcohort, patients with high levels of sGAL3 experienced shorter relapse-free survival (RFS) (p=0.048) and overall survival (OS) (p=0.021), while no such association was observed in the lung squamous cell carcinoma subcohort. Multivariate analysis indicated that sGAL3 could be an independent biomarker of prognosis for OS and RFS. Gene expression of our panel of immunoregulatory mediators was also analyzed in an independent group of 661 patients from TCGA (validation cohort), confirming the independent prognostic value of LGALS3 in the LUAD subcohort for PFS (p=0.021) and OS (p=0.004). The diagnostic, predictive and prognostic role of these immune-mediators was also evaluated in plasma samples at baseline (PRE) and at first response assessment (FR) in a cohort of 52 advanced-stage lung cancer patients treated in first-line with pembrolizumab. sFGL1, sGAL3 and its combination were also found to have a diagnostic value in this clinical setting. The Mann-Whitney test revealed that sGAL3 at FR and sMICB at PRE and FR were associated with clinical benefit in the entire cohort and in the LUAD subcohort. sCD276 was also associated with objective response in the entire cohort and in the LUAD subcohort. A Cox regression analysis identified sMICB at FR as an independent biomarker for progression-free survival (PFS) in the entire cohort and for PFS and OS in the LUAD subcohort. Furthermore, sGAL3 at PRE was found to be an independent biomarker for PFS and OS in the entire cohort, and sGAL3 at FR was identified as an independent biomarker for OS in the LUAD subcohort. A decreased in the levels of sGAL3 on treatment was associated with reduction of OS in the entire cohort. In conclusion, our findings provide relevant prognostic and predictive information on the role of GAL3 and other immune-mediators for lung cancer patients and served as the basis for developing new biomarkers and therapies., This thesis was supported by the following Spanish institutions: Centro de Investigación Biomédica en Red Cáncer (Project CB16/12/00350); Fondo de Investigación Sanitaria-Fondo Europeo de Desarrollo Regional (Projects PI15/00209, PI15/00753, PI18/00266 and IFEQ21/00194); Fundación Arnal Planelles; Generalitat Valenciana y Fondo Social Europeo (Project ACIF/2018/275): ERA-NET EURONANOMED III (Project METASTARG JTC 2018-045)
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

A Sonic Hedgehog Pathway Score to Predict the Outcome of Resected Non-Small Cell Lung Cancer Patients

  • Herreros-Pomares, Alejandro|||0000-0003-3838-097X
  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
  • Doria, Paula
  • Gallach, Sandra
  • Meri-Abad, Marina
  • Guijarro, Ricardo
  • Calabuig-Fariñas, Silvia
  • Camps, Carlos
[EN] Background Mutations and deregulations in components of the Hedgehog (Hh) pathway have been associated with cancer onset and tumor growth in different malignancies, but their role in non-small cell lung cancer (NSCLC) remains unclear. This study aims to investigate the expression pattern of the main components of the Hh pathway in tumor and adjacent normal tissue biopsies of resected NSCLC patients. Methods The relative expression of GLI1, PTCH1, SHH, and SMO was analyzed by quantitative polymerase chain reaction (PCR) in a cohort of 245 NSCLC patients. Results were validated in an independent cohort of NSCLC patients from The Cancer Genome Atlas (TCGA). Results We found that SMO and GLI1 were overexpressed in the tumor compared with normal-paired tissue, whereas PTCH1 and SHH were underexpressed. In addition, patients with higher expression levels of PTCH1 presented better outcomes. A gene expression score, called the Hedgehog Score, was calculated using a multivariable model including analyzed components of the Hh signaling pathway. NSCLC patients with a high Hedgehog Score had significantly shorter relapse-free survival (RFS) and overall survival (OS) than patients with a low score, especially at stage I of the disease. Similarly, patients in the adenocarcinoma (ADC) subcohort had shorter RFS and OS. Multivariate Cox analysis exhibited that the Hedgehog Score is an independent prognostic biomarker for OS in both the entire training cohort and the ADC subcohort. The Hedgehog Score was validated in an independent cohort of NSCLC patients from TCGA, which confirmed its prognostic value. Conclusions Our results provide relevant prognostic data for NSCLC patients and support further studies on the Hh pathway., This work was supported by grant no. CB16/12/00350 from the Centro de Investigacion Biomedica en Red de Cancer (CIBEROnc) and Grant No. PI18/00266 from the Instituto de Salud Carlos III (ISCIII).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Lung tumorspheres reveal cancer stem cell-like properties and a score with prognostic impact in resected non-small cell lung cancer

  • Herreros-Pomares, Alejandro|||0000-0003-3838-097X
  • Sirera Pérez, Rafael|||0000-0001-9162-8490
  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
  • de Maya-Gironés, J.D.
  • Calabuig-Fariñas, Silvia
  • Lucas, Rut
  • Martínez-Romero, Alicia
  • Pardo-Sánchez, José Miguel
  • Alonso, Sergio
  • Blasco-Cordellat, Ana
  • Guijarro, Ricardo
  • Martorell, Miguel
  • Escorihuela, Eva
  • Chiara, María Dolores
  • Durendez-Saez, Elena
  • Gandía, Carolina
  • Forteza, Jerónimo
  • Farràs, Rosa
  • Camps-Herrero, Carlos
[EN] The high resistance against current therapies found in non-small-cell lung cancer (NSCLC) has been associated to cancer stem-like cells (CSCs), a population for which the identification of targets and biomarkers is still under development. In this study, primary cultures from early-stage NSCLC patients were established, using sphere-forming assays for CSC enrichment and adherent conditions for the control counterparts. Patient-derived tumorspheres showed self-renewal and unlimited exponential growth potentials, resistance against chemotherapeutic agents, invasion and differentiation capacities in vitro, and superior tumorigenic potential in vivo. Using quantitative PCR, gene expression profiles were analyzed and NANOG, NOTCH3, CD44, CDKN1A, SNAI1, and ITGA6 were selected to distinguish tumorspheres from adherent cells. Immunoblot and immunofluorescence analyses confirmed that proteins encoded by these genes were consistently increased in tumorspheres from adenocarcinoma patients and showed differential localization and expression patterns. The prognostic role of genes significantly overexpressed in tumorspheres was evaluated in a NSCLC cohort (N = 661) from The Cancer Genome Atlas. Based on a Cox regression analysis, CDKN1A, SNAI1, and ITGA6 were found to be associated with prognosis and used to calculate a gene expression score, named CSC score. Kaplan¿Meier survival analysis showed that patients with high CSC score have shorter overall survival (OS) in the entire cohort [37.7 vs. 60.4 months (mo), p = 0.001] and the adenocarcinoma subcohort [36.6 vs. 53.5 mo, p = 0.003], but not in the squamous cell carcinoma one. Multivariate analysis indicated that this gene expression score is an independent biomarker of prognosis for OS in both the entire cohort [hazard ratio (HR): 1.498; 95% confidence interval (CI), 1.167¿1.922; p = 0.001] and the adenocarcinoma subcohort [HR: 1.869; 95% CI, 1.275¿2.738; p = 0.001]. This score was also analyzed in an independent cohort of 114 adenocarcinoma patients, confirming its prognostic value [42.90 vs. not reached (NR) mo, p = 0.020]. In conclusion, our findings provide relevant prognostic information for lung adenocarcinoma patients and the basis for developing novel therapies. Further studies are required to identify suitable markers and targets for lung squamous cell carcinoma patients., This work was supported by Fondo de Investigación Sanitaria, ISCIII (PI12-02838, PI12-00956, PI15-00753, PI15-00209), and Fundación Arnal Planelles. A. H.-P. and J.M.P.-S. are supported by Ministerio de Educación, Cultura y Deporte (FPU14/06911 and FPU13/02755, respectively).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer

  • Moreno-Manuel, Andrea
  • Simoes, Ines
  • Aranda, Fernando
  • Calabuig-Fariñas, Silvia
  • Carreras, Esther
  • Zuñiga, Sheila
  • Saenger, Yvone
  • Rosell, Rafael
  • Camps-Herrero, Carlos
  • Lozano, Francisco
  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
  • Sirera Pérez, Rafael|||0000-0001-9162-8490
[EN] Background: The study of immune surveillance in the tumour microenvironment is leading to the development of new biomarkers and therapies. The present research focuses on the expression of CD5 and CD6¿two lymphocyte surface markers involved in the fine tuning of TCR signaling¿as potential prognostic biomarkers in resectable stages of non-small cell lung cancer (NSCLC). Methods: CD5 and CD6 gene expression was analysed by reverse transcription quantitative polymerase chain reaction (RTqPCR) in 186 paired fresh frozen tumour and normal tissue samples of resected NSCLC. Results: Patients with higher CD5 expression had significantly increased overall survival (OS, 49.63 vs. 99.90 months, P=0.013). CD5 expression levels were correlated to CD4 infiltration and expression levels, and survival analysis showed that patients with a higher CD5/CD4+ ratio had significantly improved prognosis. Multivariate analysis established CD5 expression as an independent prognostic biomarker for OS in early stages of NSCLC (HR=0.554; 95% CI, 0.360¿0.853; P=0.007). Further survival analysis of NSCLC cases (n=97) from The Cancer Genome Atlas (TCGA) database, confirmed the prognostic value of both CD5 and CD6 expression¿ although CD6 expression alone did not reach significant prognostic value in our NSCLC training cohort. Conclusions: Our data support further studies on CD5 and CD6 as novel prognostic markers in resectable NSCLC and other cancer types (i.e., melanoma), as well as a role for these receptors in immune surveillance., This work was supported by Spanish Health Institute Carlos III (ISCII, Fondo de Investigacion Sanitaria; PI15-00753 to RS and P118/00226 to EJ and CC), Spanish Ministry of Economy, Industry and Competitiveness (MINECO, Plan Nacional de I+D+i; SAF2016-80535-R to FL) -co-financed by European Development Regional Fund "A way to achieve Europe" ERDF; Worldwide Cancer Research (14-1275 to FL), Fundacio La Marato TV3 (201319-30-31-32 to FL and YS), and Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR) from Generalitat de Catalunya (2017/SGR/1582 to FL). AM is recipient of a PhD scholarship from Asociacion Espanola Contra el Cancer (AECC) Scientific Foundation and Junta Provincial Asociada de Valencia AECC; IS, FA and EC are recipients of fellowships from Fundacao para a Ciencia e a Tecnologia (SFRH/BD/75738/2011), Sara Borrell Program from ISCIII (CD15/00016), and European Community Seventh Framework Program (BIOTRACK, FP7/2007/2013; 229673), respectively.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients

  • Usó, Marta
  • Calabuig-Farinas, Silvia
  • Blasco, Ana
  • Garcia del Olmo, Eva
  • Guijarro, Ricardo
  • Martorell, Miguel
  • Camps, Carlos
  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
  • Sirera Pérez, Rafael|||0000-0001-9162-8490
[EN] Tumors develop mechanisms to recruit tolerogenic immune cells and to induce the expression of molecules that act as immune checkpoints. This regulation of the immune microenvironment favors immune tolerance to the neoplastic cells. In this study, we have investigated the prognostic role of immune-checkpoint expression markers in a cohort of resectable non-small cell lung cancer (NSCLC) patients. RNA was isolated from fresh-frozen lung specimens (tumor and normal lung) (n = 178). RTqPCR was performed to analyze the relative expression of 20 immune-related genes that were normalized by the use of endogenous genes selected by GeNorm algorithm. Patients with higher expression levels of IL23A and LGALS2 presented better outcomes. In the clustering expression patterns, we observed that patients with higher expression of immunoregulatory genes had better survival rates. Additionally, these data were used to develop a gene expression score. Since CTLA4 and PD1 were associated with prognosis based on Cox regression analysis (Z-score > 1.5), a multivariate model including these two genes was created. Absolute regression coefficients from this analysis were used in order to calculate the immunecheckpoint score: (PD1 x 0.116) + (CTLA4 x 0.059) for each case. Kaplan-Meier survival analysis showed that patients with high immune-checkpoint score have longer overall survival (OS) [NR vs. 40.4 mo, p = 0.008] and longer relapse-free survival (RFS) [82.6 vs. 23 mo, p = 0.009]. Multivariate analysis in the entire cohort indicated that the immune-checkpoint score was an independent biomarker of prognosis for OS [HR: 0.308; 95% CI, 0.156-0.609; p = 0.001] and RFS [HR: 0.527; 95% CI, 0.298-0.933; p = 0.028] in early-stage NSCLC patients. In conclusion, this score provides relevant prognostic information for a better characterization of early stage NSCLS patients with strikingly different outcomes and who may be candidates for immune-based therapies., This work was supported by the Red Tematica de Investigacion Cooperativa en Cancer (RD12/0036/0025) and the Fondo de Investigacion Sanitaria-Fondo Europeo de Desarrollo Regional (PI09/01147, PI09/01149 and PI12/02838)
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Volatile profile of dehydrated cherry tomato: Influence of osmotic pre-treatment and microwave power

  • Heredia Gutiérrez, Ana Belén|||0000-0001-6629-9779
  • Andrés Grau, Ana María|||0000-0002-6132-3167
  • Escriche Roberto, Mª Isabel|||0000-0003-0180-0360
  • Peinado Pardo, Irene
  • Rosa Barbosa, Estela María
[EN] Vegetable flavour is a quality characteristic for consumer acceptability. Sun and air are traditionally used for drying tomatoes; however, the optimal combination of techniques such as osmotic dehydration or microwave-assisted air-drying could lead to high quality self-stable products. The aim of this paper was to study the influence of different process variables on the volatile profile of dehydrated cherry tomato halves. The analysed variables were: air-drying temperature (40 and 55 °C), microwave power (0 and 1 W/g) and previous osmotic dehydration with a 55 Brix binary sucrose solution at 30 °C for 120 min (OD1) or ternary solution of 27.5% sucrose + 10% NaCl (w/w) at 40 °C for 60 min (OD2). Twenty major volatile compounds were identified in fresh tomatoes. Among them, 2-isobutylthiazole and 6-methyl-5-hepten-2-one stand out as impact volatile compounds. Dehydration modified the volatile profile, mainly due to the changes induced in some typical fresh-like tomato compounds, but also due to the generation of five new compounds: 1-butanol, 2-methyl-2-butenal, 3-hydroxy-2-butanone, furfural, acetonitrile, related to Maillard reactions, and the catabolism of carotenoids and polyunsaturated fatty acids. Principal component analysis showed the possibility of obtaining dried cherry tomatoes with different volatile profiles, depending on drying conditions. © 2011 Elsevier Ltd. All rights reserved., Authors would like to thank Direccion General de Investigacion del Ministerio de Ciencia y Tecnologia (AGL2003-00753) for the financial support given to this investigation.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Targeted delivery of therapeutics to metastatic lung cancer cells using aptamer-conjugated nanoemulsions

  • García-Fernández, Jenifer
  • Díez-Villares, Sandra
  • Cascallar, Maria
  • Rivadulla Costa, Laura
  • Martins, Ana S.
  • Groba de Antas, Soraya
  • Tarasco, Maria Cristina
  • Pantano, Elvira
  • Taiè, Giulia
  • Bertolini, Giulia
  • García-Hernández, Marta
  • Moreno, Miguel
  • Martín, M. Elena
  • Munera-Maravilla, Ester
  • Calabuig-Fariñas, Silvia
  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
[EN] Lung cancer is the primary cause of cancer-related deaths, with a five-year overall survival rate of 15 %, mainly related to late diagnosis at advanced stages. Despite recent improvements in cancer medicine, metastatic disease still, in fact, represents the main challenge for effective therapies. Targeting disseminated cells requires a better understanding of the underlying biological mechanisms and a paradigm shift to devise innovative treatments. Nanomedicine could open up new perspectives in cancer management, as nanoparticles offer many advantages in drug delivery due to their intrinsic properties, such as better bioavailability and the potential for selective targeting. A strategy to enhance delivery at the site of action is to use nanomedicines targeting specific receptors overexpressed in cancer cells or the tumor microenvironment. We recently identified TAS1R3 as an ideal target, enriched in metastatic lung cancer cells and highly expressed in the CD133+ cancer stem cell (CSC) subset. We developed and evaluated a targeted formulation of sphingomyelin nanoemulsions functionalized with a TAS1R3-specific aptamer (SN-5F). SN-5F exhibited high stability in both aqueous media and biofluids and was efficiently internalized by cell models overexpressing the targeted receptor, including the usually hard-to-target CD133+ CSC population. SN-5F was evaluated in 2D and 3D cell cultures, as well as in vivo using patient-derived xenografts, where it successfully reached disseminated cancer cells and delivered hydrophobic drugs to CSCs, resulting in reduced tumor-forming potential. These results highlight the promise of rationally designed, receptor-targeted nanomedicines as a novel approach for anti-metastatic lung cancer therapy., The authors thank the financial support given by Xunta de Galicia by Grupos de Potencial Crecemento (GPC IN607B2024/14) funded by Axencia Galega de Innovacion (GAIN) , Conselleria de Economia, Emprego e Industria, and RTC2019-07227-1 (Ministry of Economy and Competitiveness, Spain) , co-financed by the European Development Regional Fund "A way to achieve Europe" (ERDF) . This research has been funded by the Instituto de Salud Carlos III (ISCIII) through the grant PI15/00753, CB16/12/00350 Centro de Investigacion Biomedica en Red de Cancer (CIBERONC) , and AC18/00045, co-financed by the European Regional Development Fund (FEDER) by the ERA-NET Euro-NanoMed III, project METASTARG. Funding from Fundacion Cientifica Asociacion Espanola Contra el Cancer (IDEAS18153DELA and LAB-AE211721DELA is also acknowledged. LRC acknowledges Ministerio de Universidades (FPU20/07487) , and SGDA was supported by Xunta de Galicia (ED481A 2022/392) . MM has been funded by the grant PTQ2018-010067 from Ministerio de Ciencia, Innovacion y Universidades by the Spain Government. This work was partly supported by grants from the Italian Ministry of Health (RF-2021-12371959 to LR) , AIRC (IG21431 to LR) and PNRR (PNRR-POC-2022-12376329 to LR) . This work was also supported by the PROMISE project funded through the Caixa Health Research program from La Caixa Foundation (HR20-00637) as well as by the IBEROS+ project (0072_IBEROS_MAIS_1_E) funded through the Interreg POCTEP program. ASM acknowledges the financial support from Fundacao para a Ciencia e Tecnologia (FCT) for the PhD scholarship 2022. 14120.BDANA.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publication Artículo científico (JournalArticle)

Topography of the Young Galactic Disk: Spatial and Kinematic Patterns of Clustered Star Formation in the Solar Neighborhood

  • Alfaro, Emilio J.
  • Jiménez, Manuel
  • Sánchez Gil, María del Carmen
  • Sánchez, Néstor
  • González, Marta
  • Maíz Apellániz, Jesús
The accuracy in determining the spatial-kinematical parameters of open clusters makes them ideal tracers of the Galactic structure. Young open clusters (YOCs) are the main representatives of the clustered star formation mode, which identifies how most of the stars in the Galaxy form. We apply the Kriging technique to a sample of Gaia YOCs within a 3.5 kpc radius around the Sun and log(age) <= 7.5, as the age in years, to obtain Z(X, Y) and V ( Z )(X, Y) maps. Previous work by Alfaro et al. has shown that Kriging can provide reliable results even with small data samples (N similar to 100). We approach the 3D spatial and vertical velocity field structure of the Galactic disk defined by YOCs and analyze the hierarchy of the stellar cluster formation, which shows a rich hierarchical structure, displaying complexes embedded within each other. We discuss the fundamental characteristics of the methodology used to perform the mapping and point out the main results obtained in phenomenological terms. Both the 3D spatial distribution and the vertical velocity field reveal a complex disk structure with a high degree of substructures. Their analysis provides clues about the main physical mechanisms that shape the phase space of the clustered star formation in this Galactic area. Warp, corrugations, and high local deviations in Z and V ( Z ) appear to be intimately connected, in a single but intricate scenario.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Anthropometry in antipsychotic-naïve first-episode psychosis patients: An exploratory approach to the role of environmental early life events in two independent samples

  • García-Rizo, Clemente
  • Crespo-Facorro, Benedicto
  • Oliveira, Cristina
  • Gómez Revuelta, Marcos
  • Kirkpatrick, Brian
  • Son, Jacqueline Mayoral-van
  • Cayón de la Hoz, Laura
  • Garriga, Marina
  • Garrido-Torres, Nathalia
  • Bernardo, Miguel
  • Fernández-Egea, Emilio
  • Vázquez-Bourgon, Javier
[Background] Patients with schizophrenia exhibit a reduced life expectancy mainly due to medical-related pathologies which might have been initiated due to stressful events during fetal development. Indeed, intra-uterus growth patterns predict anthropometric measures in adulthood, describing risk factors for schizophrenia and metabolic disorders. We aim to evaluate anthropometric values in two cohorts of antipsychotic-naïve first-episode episode psychosis (FEP) and correlated them with surrogate markers of the fetal environment such as birth weight (BW) and season of birth., [Methods] BW, season of birth, and anthropometric values from 2 cohorts of FEP patients (Barcelona and Santander) were evaluated. In cohort B, 91 patients, and 110 controls while in cohort S, 644 and 235 were included respectively., [Results] Patients were shorter, slimmer, and with lower BMI compared with controls. In both cohorts, patients, and female patients born in winter displayed the shortest height. Regarding BW, height was significantly associated with the interaction of diagnosis and BW in the whole sample and the male subsample., [Conclusions] Our results confirm reduced anthropometric features in FEP at onset while suggesting the influence of winter birth and BW, highlighting the role of early life events in the later outcome of FEP with sex differences., Funding for this study was provided by grant RO1 DK069265 - National Institute of Diabetes and Digestive and Kidney Diseases (Dr. Kirkpatrick), PI14/00753 and PI20/00661 (Dr. Garcia-Rizo) PI08/0208; PI11/00325 and PI14/00612 (Dr.Bernardo), funded by the Carlos III Health Institute (ISCIII) and co-financed by the European Union, Centro de Investigación Biomédica en Red de salud Mental, CIBERSAM, ERCA Program / Generalitat de Catalunya And Secretaria d’Universitats i Recerca del Departament d’Economia I Coneixement (2017SGR1355). Departament de Salut de la Generalitat de Catalunya, en la convocatoria corresponent a l’any 2017 de concessió de subvencions del Pla Estratègic de Recerca i Innovació en Salut (PERIS) 2016-2020, SLT006/17/00345. This work and the research tasks carried out in the Santander cohort (PAFIP) were supported by the Instituto de Salud Carlos III and co-financed by the European Union (PI020499, PI050427 and PI060507; Prof. Crespo-Facorro) and the Valdecilla Institute of Biomedical Research (grant no. INT/A20/04 and INT/A21/10; Dr. Vázquez-Bourgon). Dr. Fernandez-Egea is supported by the 2022 MRC/NIHR CARP award (MR/W029987/1) and this research was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Protein content of blood-derived extracellular vesicles: An approach to the pathophysiology of cerebral hemorrhage

  • Laso-García, Fernando
  • Piniella, Dolores
  • Gómez-de Frutos, Mari Carmen
  • Casado-Fernández, Laura
  • Pérez-Mato, María
  • Alonso-López, Elisa
  • Otero-Ortega, Laura
  • Bravo, Susana Belén
  • Chantada-Vázquez, María Del Pilar
  • Trilla-Fuertes, Lucía
  • Fresno-Vara, Juan Ángel
  • Fuentes, Blanca
  • Díez-Tejedor, Exuperio
  • Gutiérrez-Fernández, María
  • Alonso De Leciñana, María
Introduction: Extracellular vesicles (EVs) participate in cell-to-cell paracrine signaling and can be biomarkers of the pathophysiological processes underlying disease. In intracerebral hemorrhage, the study of the number and molecular content of circulating EVs may help elucidate the biological mechanisms involved in damage and repair, contributing valuable information to the identification of new therapeutic targets. Methods: The objective of this study was to describe the number and protein content of blood-derived EVs following an intracerebral hemorrhage (ICH). For this purpose, an experimental ICH was induced in the striatum of Sprague-Dawley rats and EVs were isolated and characterized from blood at baseline, 24 h and 28 days. The protein content in the EVs was analyzed by mass spectrometric data-dependent acquisition; protein quantification was obtained by sequential window acquisition of all theoretical mass spectra data and compared at pre-defined time points. Results: Although no differences were found in the number of EVs, the proteomic study revealed that proteins related to the response to cellular damage such as deubiquitination, regulation of MAP kinase activity (UCHL1) and signal transduction (NDGR3), were up-expressed at 24 h compared to baseline; and that at 28 days, the protein expression profile was characterized by a higher content of the proteins involved in healing and repair processes such as cytoskeleton organization and response to growth factors (COR1B) and the regulation of autophagy (PI42B). Discussion: The protein content of circulating EVs at different time points following an ICH may reflect evolutionary changes in the pathophysiology of the disease., This work was supported by the Spanish Ministry of Health-Carlos III Health Institute (ISCIII) and the European Regional Development Fund (FEDER Funding) under grant PI17/01922 and PI20/00243, the Invictus Plus network under grant RD16/0019/0005, RICORS network under grant RD21/0006/0012, Miguel Servet under grant CPII20/00002 to MG-F; CP20/00024 to LO-O, Sara Borrell under grant CD19/00033 to MP-M, Ministerio de Universidades, Plan de Recuperación, Transformación y Resiliencia, Universidad Autónoma de Madrid under grant CA1/RSUE/2021-00753 to DP, and the Spanish Ministry of Health-Carlos III Health Institute (ISCIII) under grant FI18/00026 to FL-G, FI17/00188 to MG-F., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Difficulties during delivery, brain ventricle enlargement and cognitive impairment in first episode psychosis

  • Costas-Carrera, Ana
  • Verdolini, Norma
  • Garcia-Rizo, Clemente
  • Mezquida, Gisela
  • Janssen, Joost
  • Valli, Isabel
  • Corripio, Iluminada
  • Sanchez-Torres, Ana M.
  • Bioque, Miquel
  • Lobo, Antonio
  • Gonzalez-Pinto, Ana
  • Rapado-Castro, Marta
  • Vieta, Eduard
  • De la Serna, Helena
  • Mane, Anna
  • Roldan, Alexandra
  • Crossley, Nicolas
  • Penades, Rafael
  • Cuesta, Manuel J.
  • Parellada, Mara
  • Bernardo, Miquel
Patients with a first episode of psychosis (FEP) display clinical, cognitive, and structural brain abnormalities at illness onset. Ventricular enlargement has been identified in schizophrenia since the initial development of neuroimaging techniques. Obstetric abnormalities have been associated with an increased risk of developing psychosis but also with cognitive impairment and brain structure abnormalities. Difficulties during delivery are associated with a higher risk of birth asphyxia leading to brain structural abnormalities, such as ventriculomegaly, which has been related to cognitive disturbances. Methods We examined differences in ventricular size between 142 FEP patients and 123 healthy control participants using magnetic resonance imaging. Obstetric complications were evaluated using the Lewis–Murray scale. We examined the impact of obstetric difficulties during delivery on ventricle size as well as the possible relationship between ventricle size and cognitive impairment in both groups. Results FEP patients displayed significantly larger third ventricle size compared with healthy controls. Third ventricle enlargement was associated with diagnosis (higher volume in patients), with difficulties during delivery (higher volume in subjects with difficulties), and was highest in patients with difficulties during delivery. Verbal memory was significantly associated with third ventricle to brain ratio. Conclusions Our results suggest that difficulties during delivery might be significant contributors to the ventricular enlargement historically described in schizophrenia. Thus, obstetric complications may contribute to the development of psychosis through changes in brain architecture.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Competition between superconductor, ferromagnetic stray magnetic fields in YBa2Cu3O7-x films pierced with Co nano-rods

  • Rouco Gómez, Víctor
  • Córdoba, R.
  • De Teresa, J. M.
  • Rodríguez, L. A.
  • Navau, Carles|||0000-0003-4763-5305
  • Valle, Nuria del|||0000-0003-2608-5009
  • Via, Guillem|||0000-0002-4789-1600
  • Sánchez Moreno, Álvaro|||0000-0002-2988-0289
  • Monton, Carlos
  • Kronast, F.
  • Obradors, Xavier|||0000-0003-4592-7718
  • Puig i Molina, Mª Teresa|||0000-0002-1873-0488
  • Palau, Anna|||0000-0002-2217-164X
Superconductivity and ferromagnetism are two antagonistic phenomena that combined can lead to a rich phenomenology of interactions, resulting in novel physical properties and unique functionalities. Here we propose an original hybrid system formed by a high-temperature superconducting film, patterned with antidots, and with ferromagnetic nano-rods grown inside them. This particular structure exhibits the synergic influence of superconductor (SC) - ferromagnetic (FM) stray fields, in both the superconducting behaviour of the film and the three-dimensional (3D) magnetic structure of nano-rods. We show that FM stray fields directly influence the critical current density of the superconducting film. Additional functionalities appear due to the interaction of SC stray fields, associated to supercurrent loops, with the non-trivial 3D remanent magnetic structure of FM nano-rods. This work unravels the importance of addressing quantitatively the effect of stray magnetic fields from both, the superconductor and the ferromagnet in hybrid magnetic nano-devices based on high temperature superconductors.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Geometrically controlled ratchet effect with collective vortex motion

  • Rouco Gómez, Víctor
  • Palau, Anna|||0000-0002-2217-164X
  • Monton, Carlos
  • Valle, Nuria del|||0000-0003-2608-5009
  • Navau, Carles|||0000-0003-4763-5305
  • Sánchez Moreno, Álvaro|||0000-0002-2988-0289
  • Obradors, Xavier|||0000-0003-4592-7718
  • Puig i Molina, Mª Teresa|||0000-0002-1873-0488
Rectified flux motion arising from the collective effect of many interacting vortices is obtained in a specially designed superconducting device. Ratchet structures with different asymmetric pinning potentials are generated by tuning the size, depth, and distribution of triangular blind-antidots in a high-temperature superconducting film. We experimentally and theoretically demonstrate that the amplitude and sign of the rectified vortex motion can be finely tuned with the pattern geometry. Two different dynamical regimes depending on the nature of vortices initiating the dissipation are identified, which can control the rectified vortex motion.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Focus-background articulation in Spanish qualitative binominal NPs

  • Villalba, Xavier|||0000-0001-6993-976X
The goal of this article is to show that, unlike recent analyses of the qualitative binominal NP construction (QBNP) that idiot of a doctor/el idiota del médico, Spanish QBNPs require an analysis with the following features: (i) the definite article preceding the subject nominal is a fully-fledged determiner, (ii) the predicate-subject final word order is the consequence of predicate focus fronting, (iii) the subject receives background interpretation, and (iv) as a consequence of its interpretation as background, the subject of the construction must be specific, which explains the apparently syntactic restrictions on the size of the nominals occurring in this position. This proposal is shown to extend straightforwardly to a kindred Spanish nominalizing construction, yielding a better understanding of the role of focus in DP structure
Dipòsit Digital de Documents de la UAB
Publication

FcγRIIb-BCR co-ligation inhibits B-cell receptor signaling in chronic lymphocytic leukemia

  • Bosch, Rosa|||0000-0002-7596-183X
  • Mora, Alba|||0000-0003-1064-8495
  • Cuellar, Carolina
  • Ferrer, Gerardo|||0000-0002-4084-6815
  • Gorlatov, Sergey
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Montserrat, Emili
  • Sierra, Jorge|||0000-0002-7966-0356
  • Rai, Kanti R.
  • Chiorazzi, Nicholas
  • Moreno, Carol|||0000-0003-3275-0271
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Current Approach in the Management of Secondary Immunodeficiency in Patients with Hematological Malignancies, Spanish Expert Consensus Recommendations

  • Boque, Concepcion
  • Sánchez Ramón, Silvia|||0000-0001-9585-6167
  • Córdoba, Raúl|||0000-0002-7654-8836
  • Moreno, Carol|||0000-0003-3275-0271
  • Cabezudo, Elena
A Delphi-based survey was designed to assess the opinions of clinical hematologists (n = 17) and clinical immunologists (n = 18) from across Spain on secondary immunodeficiencies (SID) in the management of oncohematological patients. There was 100% agreement on the need to have available guidelines for the management of immunodeficiency in hematological patients; to perform a baseline immunological evaluation in patients with chronic lymphocytic leukemia (CLL), multiple myeloma (MM), lymphoma and hematopoietic stem cell transplantation (HSCT) recipients; and to quantify serum IgG, IgA and IgM levels when SID is suspected. More than 90% agreed on the need for active immunization against seasonal influenza and H1N1, pneumococcus and Haemophilus influenzae. There was a consensus on the monitoring of IgG levels every 3 months (83%) and the need to have available a clinical protocol for the use of IVIG in the management of SID (94%), to monitor trough IgG levels to determine the correct IVIG dose (86%) and to discontinue IVIG after the recovery of IgG levels after 12 months of follow-up (77%). The findings of the present survey may be useful recommendations for hematologists and immunologists to improve the management of SID in daily practice.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

The role of premorbid IQ and age of onset as useful predictors of clinical, functional outcomes, and recovery of individuals with a first episode of psychosis

  • Molina-García, Mariola
  • Fraguas, David
  • Rey-Mejías, Ángel del
  • Mezquida, Gisela
  • Sánchez Torres, Ana María
  • Amoretti, Silvia
  • Lobo, Antonio
  • González Pinto, Ana
  • Andreu-Bernabeu, Álvaro
  • Corripio, Iluminada
  • Vieta, Eduard
  • Baeza, Inmaculada
  • Mané, Anna
  • Cuesta, Manuel J.
  • Serna, Elena de la
  • Payá, Beatriz
  • Zorrilla, Iñaki
  • Arango, Celso
  • Bernardo, Miguel
  • Rapado-Castro, Marta
  • Parellada, Mara
  • PEPs Group
Background: premorbid IQ (pIQ) and age of onset are predictors of clinical severity and long-term functioning after a first episode of psychosis. However, the additive influence of these variables on clinical, functional, and recovery rates outcomes is largely unknown. Methods: we characterized 255 individuals who have experienced a first episode of psychosis in four a priori defined subgroups based on pIQ (low pIQ < 85; average pIQ ≥ 85) and age of onset (early onset < 18 years; adult onset ≥ 18 years). We conducted clinical and functional assessments at baseline and at two-year follow-up. We calculated symptom remission and recovery rates using the Positive and Negative Symptoms of Schizophrenia Schedule (PANSS) and the Global Assessment Functioning (GAF or Children-GAF). We examined clinical and functional changes with pair-wise comparisons and two-way mixed ANOVA. We built hierarchical lineal and logistic regression models to estimate the predictive value of the independent variables over functioning or recovery rates. Results: early-onset patients had more severe positive symptoms and poorer functioning than adult-onset patients. At two-year follow-up, only early-onset with low pIQ and adult-onset with average pIQ subgroups differed consistently, with the former having more negative symptoms (d = 0.59), poorer functioning (d = 0.82), lower remission (61% vs. 81.1%), and clinical recovery (34.1% vs. 62.2%). Conclusions: early-onset individuals with low pIQ may present persistent negative symptoms, lower functioning, and less recovery likelihood at two-year follow-up. Intensive cognitive and functional programs for these individuals merit testing to improve long-term recovery rates in this subgroup., This work was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III, PI02/1248, PI03032, PI05/0678, PI08/0208 PI09/01442, PI11/00325, PI12/1303, PI14/00612, PI15/00723, PI17/009977, PI18/00753 cofinanced by ERDF Funds from the European Commission, 'A way of making Europe', CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2). The CERCA Program/Generalitat de Catalunya And Secretaria d'Universitats i Recerca del Departament d'Economia I Coneixement (2017SGR1355). Departament de Salut de la Generalitat de Catalunya, en la convocatoria corresponent a l'any 2017 de concessió de subvencions del Pla Estratègic de Recerca i Innovació en Salut (PERIS) 2016-2020, modalitat Projectes de recerca orientats a l'atenció primària, amb el codi d'expedient SLT006/17/00345. European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7-HEALTH-2009-2.2.1-3-242114 (Project OPTi-MISE), FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7-HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz and Fundación Mutua Madrileña.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

TMPRSS4: a novel tumor prognostic indicator for the stratification of stage ia tumors and a liquid biopsy biomarker for NSCLC patients

  • Villalba, María
  • Expósito, Francisco
  • Pajares Villandiego, María Josefa
  • Sáinz, Cristina
  • Redrado, Miriam
  • Remírez, Ana
  • Wistuba, Ignacio
  • Behrens, Carmen
  • Jantus-Lewintre, Eloisa
  • Camps, Carlos
  • Montuenga, Luis M.
  • Pío, Rubén
  • Lozano, María Dolores
  • Andrea, Carlos de
  • Calvo, Alfonso
Relapse rates in surgically resected non-small-cell lung cancer (NSCLC) patients are between 30% and 45% within five years of diagnosis, which shows the clinical need to identify those patients at high risk of recurrence. The eighth TNM staging system recently refined the classification of NSCLC patients and their associated prognosis, but molecular biomarkers could improve the heterogeneous outcomes found within each stage. Here, using two independent cohorts (MDA and CIMA-CUN) and the eighth TNM classification, we show that TMPRSS4 protein expression is an independent prognostic factor in NSCLC, particularly for patients at stage I: relapse-free survival (RFS) HR, 2.42 (95% CI, 1.47–3.99), p < 0.001; overall survival (OS) HR, 1.99 (95% CI, 1.25–3.16), p = 0.004). In stage IA, high levels of this protein remained associated with worse prognosis (p = 0.002 for RFS and p = 0.001 for OS). As TMPRSS4 expression is epigenetically regulated, methylation status could be used in circulating tumor DNA from liquid biopsies to monitor patients. We developed a digital droplet PCR (ddPCR) method to quantify absolute copy numbers of methylated and unmethylated CpGs within the TMPRSS4 and SHOX2 (as control) promoters in plasma and bronchoalveolar lavage (BAL) samples. In case-control studies, we demonstrated that TMPRSS4 hypomethylation can be used as a diagnostic tool in early stages, with an AUROC of 0.72 (p = 0.008; 91% specificity and 52% sensitivity) for BAL and 0.73 (p = 0.015; 65% specificity and 90% sensitivity) for plasma, in early stages. In conclusion, TMPRSS4 protein expression can be used to stratify patients at high risk of relapse/death in very early stages NSCLC patients. Moreover, analysis of TMPRSS4 methylation status by ddPCR in blood and BAL is feasible and could serve as a non-invasive biomarker to monitor surgically resected patients., This work has been funded by PIUNA to C.A., ISC-III (PI16/01352, to A.C.; PI17/0041 to R.P.; PI15/00753; PI16/01821 to L.M.M., and CB16/12/00350 to E.J.L.; CIBERONC CB16/12/00443 to L.M.M.), Juan Serrano, AECC, and Ramón Areces Foundations (to L.M.M.).M.V. was supported by “FPU, Spanish Ministry of Education”; F.E. was funded by "Asociación de Amigos de la Universidad de Navarra" in association with "La Caixa" Banking Foundation.